ABBOTINDIABSEAbbott India Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 15 May, 2025 · 18:55 IST

Outcome of Board Meeting

ABBOTINDIA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.0%Reaction day
₹30230.00
prior close
₹31000.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.9%+0.1% vs market
Pharmaceuticals peers, median of 150sector+0.2%+0.8% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.0
10m
+0.2
15m
-0.3
30m
-0.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.0+0.9+0.1+0.2+0.8
Next day
+1.6+1.0+0.5+1.1+0.4
2d
+2.2-0.6+2.7+0.1+2.0
3d
+3.9+0.2+3.6+1.0+2.9
4d
+2.8-0.1+2.9+1.2+1.6
5d
+1.8+0.4+1.4+0.7+1.1
1w
+0.6+1.2-0.6+1.4-0.7
15d
+3.5+4.4-0.8+0.6+2.9
1m
+4.8+3.9+0.9+2.1+2.7
2m
+12.9+5.8+7.0+3.8+9.1
3m
+7.8+2.3+5.5-1.0+8.8
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Abbott India's board approved audited financial results for Q4 and FY ended March 31, 2025, with the statutory auditor Walker Chandiok & Co LLP issuing an unmodified opinion. Full-year revenue from operations grew about 9.6% to Rs. 6,409.15 crore, while profit after tax rose roughly 17.7% to Rs. 1,414.44 crore (EPS of Rs. 665.62 vs Rs. 565.28). Q4 standalone revenue stood at Rs. 1,604.59 crore with PAT of Rs. 367.04 crore, up about 27.9% year-on-year. The board recommended a final dividend of Rs. 475 per share (up from Rs. 410 last year), with record date July 25, 2025 and AGM scheduled for August 13, 2025. The board also appointed Joshi Apte & Associates as cost auditors for FY26 and BNP & Associates as secretarial auditors for FY26-FY30.

Likely market impact

A healthy double-digit profit growth and a 15.9% hike in the final dividend signal strong shareholder rewards and continued business momentum. The clean auditor report and routine governance appointments are neutral to positive for the stock.